uniQure Announces $150M Public Offering After Recent Share Capital Increase
Summary
uniQure announced a proposed $150 million public offering of ordinary shares and pre-funded warrants. This capital raise follows shareholder approval on June 15th to increase authorized share capital, enabling this financing. The offering provides significant funding for the company's gene therapy pipeline, including AMT-130 which recently received positive FDA feedback, but will also result in dilution for existing shareholders.
At the time of this announcement, QURE was trading at $45.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $8.73 to $71.50. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.